Bevacizumab and Atezolizumab for Unresectable Hepatocellular Carcinoma: Real-world Data in Taiwan-Tainan Medical Oncology Group H01 Trial

YANG-CHENG LEE; WEN-TSUNG HUANG; MING-YANG LEE; CHAO-JUNG TSAO; YIN-HSUN FENG

doi:10.21873/invivo.13099

Research ArticleClinical Studies

Open Access

Bevacizumab and Atezolizumab for Unresectable Hepatocellular Carcinoma: Real-world Data in Taiwan-Tainan Medical Oncology Group H01 Trial

YANG-CHENG LEE, WEN-TSUNG HUANG, MING-YANG LEE, CHAO-JUNG TSAO and YIN-HSUN FENG

In Vivo January 2023, 37 (1) 454-460; DOI: https://doi.org/10.21873/invivo.13099

YANG-CHENG LEE

1Division of Hematology and Oncology, Department of Internal Medicine, Tainan Municipal Hospital (Managed by Show Chwan Medical Care Corporation), Tainan, Taiwan, R.O.C.;

2Chung Hwa University of Medical Technology, Tainan, Taiwan, R.O.C.;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

WEN-TSUNG HUANG

3Division of Hematology and Oncology, Department of Internal Medicine, Chi Mei Medical Center, Tainan, Taiwan, R.O.C.;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

MING-YANG LEE

4Department of Internal Medicine, Chia-Yi Christian Hospital, Chia-Yi, Taiwan, R.O.C.;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

CHAO-JUNG TSAO

3Division of Hematology and Oncology, Department of Internal Medicine, Chi Mei Medical Center, Tainan, Taiwan, R.O.C.;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site
For correspondence: cjt@mail.chimei.org.tw

YIN-HSUN FENG

5Division of Hematology and Oncology, Department of Internal Medicine, Chi Mei Medical Center, Tainan, Taiwan, R.O.C.

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site
For correspondence: yinhsun.feng@gmail.com

Article
Figures & Data
Info & Metrics
PDF

Article Figures & Data

Figures

Tables

Download figure
Open in new tab
Download powerpoint
Figure 1.
Kaplan-Meier curves of (A) progression-free survival and (B) overall survival.
Download figure
Open in new tab
Download powerpoint
Figure 2.
Kaplan-Meier curves of (A) progression-free survival and (B) overall survival, categorized by lines of treatment.
Download figure
Open in new tab
Download powerpoint
Figure 3.
Kaplan-Meier curves of (A) progression-free survival and (B) overall survival, categorized by the dosage of bevacizumab. LD: Low dose; SD: standard dose.

Tables

Figures

PreviousNext

In this issue

In Vivo

Vol. 37, Issue 1

January-February 2023

Table of Contents
Table of Contents (PDF)
About the Cover
Index by author
Back Matter (PDF)
Ed Board (PDF)
Front Matter (PDF)

Download PDF

Article Alerts

User Name *

Password *

Email *

Email Article

Thank you for your interest in spreading the word on In Vivo.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Your Email *

Your Name *

Send To *

Enter multiple addresses on separate lines or separate them with commas.

You are going to email the following Bevacizumab and Atezolizumab for Unresectable Hepatocellular Carcinoma: Real-world Data in Taiwan-Tainan Medical Oncology Group H01 Trial

Message Subject (Your Name) has sent you a message from In Vivo

Message Body (Your Name) thought you would like to see the In Vivo web site.

Your Personal Message

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Math question * 5 + 1 =

Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.

Citation Tools

Bevacizumab and Atezolizumab for Unresectable Hepatocellular Carcinoma: Real-world Data in Taiwan-Tainan Medical Oncology Group H01 Trial

YANG-CHENG LEE, WEN-TSUNG HUANG, MING-YANG LEE, CHAO-JUNG TSAO, YIN-HSUN FENG

In Vivo Jan 2023, 37 (1) 454-460; DOI: 10.21873/invivo.13099

Citation Manager Formats

BibTeX
Bookends
EasyBib
EndNote (tagged)
EndNote 8 (xml)
Medlars
Mendeley
Papers
RefWorks Tagged
Ref Manager
RIS
Zotero

Reprints and Permissions

Bevacizumab and Atezolizumab for Unresectable Hepatocellular Carcinoma: Real-world Data in Taiwan-Tainan Medical Oncology Group H01 Trial

YANG-CHENG LEE, WEN-TSUNG HUANG, MING-YANG LEE, CHAO-JUNG TSAO, YIN-HSUN FENG

In Vivo Jan 2023, 37 (1) 454-460; DOI: 10.21873/invivo.13099

Share This Article:

Tweet Widget
Facebook Like
Google Plus One

Jump to section

Article
Figures & Data
Info & Metrics
PDF

No related articles found.

PubMed
Google Scholar

Cited By...

No citing articles found.

Google Scholar

Keywords

Antiangiogenic therapy
hepatocellular carcinoma
Immune checkpoint inhibitor
real world data

Main menu

User menu

Search

Bevacizumab and Atezolizumab for Unresectable Hepatocellular Carcinoma: Real-world Data in Taiwan-Tainan Medical Oncology Group H01 Trial

Article Figures & Data

Figures

Tables

In this issue

Citation Manager Formats

Related Articles

Cited By...

More in this TOC Section

Similar Articles

Keywords